Page last updated: 2024-11-02

pioglitazone and Retroperitoneal Fibrosis

pioglitazone has been researched along with Retroperitoneal Fibrosis in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Retroperitoneal Fibrosis: A slowly progressive condition of unknown etiology, characterized by deposition of fibrous tissue in the retroperitoneal space compressing the ureters, great vessels, bile duct, and other structures. When associated with abdominal aortic aneurysm, it may be called chronic periaortitis or inflammatory perianeurysmal fibrosis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Matsuhashi, N1
Watanabe, K1
Kanamori, H1
Ohnishi, S1
Omata, M1

Other Studies

1 other study available for pioglitazone and Retroperitoneal Fibrosis

ArticleYear
PPARgamma agonists for intestinal ischaemia.
    Lancet (London, England), 2001, Jul-07, Volume: 358, Issue:9275

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents;

2001